A comparative analysis of clinical and molecular factors with the stage of cervical cancer in a Brazilian cohort

Simple item page
dc.contributor.authorAmaro-Filho, Sergio M.
dc.contributor.authorGolub, Jonathan E.
dc.contributor.authorNuovo, Gerard J.
dc.contributor.authorCunha, Cynthia B.
dc.contributor.authorLevi, José E.
dc.contributor.authorVilla, Luisa L.
dc.contributor.authorAndrade, Cecília V.
dc.contributor.authorRussomano, Fabio B.
dc.contributor.authorTristão, Aparecida
dc.contributor.authorPires, Andrea
dc.contributor.authorNicol, Alcina F.
dc.date.accessioned2023-01-19T16:43:44Z
dc.date.available2023-01-19T16:43:44Z
dc.date.issued2013-03-07
dc.description.abstractCell cycle protein expression plays an important role in the pathophysiology of cervical cancer. However, few studies have attempted to correlate the use of these biomarkers with the clinical progression of the tumor. Objectives: 1) To analyze the expression of Ki-67, p53 and p16INK4a in cervical cancer, 2) to correlate the relative expression of these proteins as well as clinical parameters with the stage of disease, and 3) to determine the HPV DNA prevalence and subtype distribution. Methods: Tissue Micro-Arrays (TMA) from patients with invasive cervical cancer (ICC) and controls were analyzed. HPV DNA detection was done by PCR and in situ hybridization. Ki-67, p53 and p16INK4a were analyzed by immunohistochemistry; clinical data was derived from the chart review. Results: Advanced tumor stage (III and IV) was strongly associated (p<0.005) with advanced age (>55 years old), with more than four pregnancies and with the lack of formal education. HPV DNA was found in 94.3% of cases with the most prevalent types being HPV16 (67.5%), followed by HPV33 (12.0%) and HPV35 (3.6%). High expression of Ki-67 and p16 was more common in the advanced FIGO stages (p = 0.023). Women with HPV16 tended to be younger (50.9 years; SE 1.9) compared to women with other types (59.9 years; SE 2.8). Conclusion: We found that Ki-67 and p16 expression were independently associated with the tumor stage. We also noted that about 1/3 of the cervical cancers in this Brazilian cohort were not associated with HPV types directly targeted by the current HPV vaccines.en_US
dc.identifier.citationAmaro-Filho, S. M., Golub, J. E., Nuovo, G. J., Cunha, C. B., Levi, J. E., Villa, L. L., Andrade, C. V., Russomano, F. B., Tristão, A., Pires, A., & Nicol, A. F. (2013). A comparative analysis of clinical and molecular factors with the stage of cervical cancer in a Brazilian cohort. PloS one, 8(3), e57810. https://doi.org/10.1371/journal.pone.0057810en_US
dc.identifier.otherDOI: 10.1371/journal.pone.0057810
dc.identifier.urihttps://hdl.handle.net/20.500.14041/5680
dc.language.isoen_USen_US
dc.publisherPloS Oneen_US
dc.rightsAttribution-NonCommercial-NoDerivs 3.0 United States*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/3.0/us/*
dc.subjectComparative Analysisen_US
dc.subjectClinical and Molecular Factorsen_US
dc.subjectStage of Cervical Canceren_US
dc.subjectBrazilian Cohorten_US
dc.titleA comparative analysis of clinical and molecular factors with the stage of cervical cancer in a Brazilian cohorten_US
dc.typeArticleen_US
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
pone.0057810.pdf
Size:
1.07 MB
Format:
Adobe Portable Document Format
Description:
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.65 KB
Format:
Item-specific license agreed upon to submission
Description:
Download
Collections
SRHR Evidence (Best practice, Systematic reviews)